News Column

Researchers from Merck & Company Report Findings in Immunotherapy

June 4, 2014

By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Researchers detail new data in Biotechnology. According to news reporting out of Whitehouse Station, New Jersey, by NewsRx editors, research stated, "Previous nationwide surveys of allergies in the United States have focused on nasal symptoms, but ocular symptoms are also relevant. This study determines the effects of ocular and nasal allergies on patients' lives."

Our news journalists obtained a quote from the research from Merck & Company, "Telephone surveys of randomly selected U.S. households (the patient survey) and health care providers (provider survey) were conducted in the United States in 2012. Study participants were 2765 people >= 5 years of age who had ever been diagnosed with nasal or ocular allergies and 500 health care providers in seven specialties. Respondents to the patient survey reported a bimodal seasonal distribution of allergy symptoms, with peaks in March to May and September. Nasal congestion was the most common of the symptoms rated as 'extremely bothersome' (39% of respondents), followed by red, itchy eyes (34%; p = 0.84 for difference in extreme bothersomeness of nasal and ocular symptoms). Twenty-nine percent of respondents reported that their or their child's daily life was impacted 'a lot' when allergy symptoms were at their worst. Workers rated their mean productivity at 29% lower when allergy symptoms were at their worst (p < 0.001 compared with no symptoms). Providers reported that itchy eyes was the symptom causing most patients to seek medical treatment by pediatricians (73%), ophthalmologist/optometrists (72%), and nurse practitioners or physician assistants (62%), whereas nasal congestion was the symptom causing most patients to seek treatment from otolaryngologists (85%), allergist/immunologists (79%), and family medicine practitioners (64%)."

According to the news editors, the research concluded: "Ocular and nasal allergy symptoms substantially affected patients' lives and were comparable in their impact."

For more information on this research see: Ocular and nasal allergy symptom burden in America: The Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) surveys. Allergy and Asthma Proceedings, 2014;35(3):211-218. Allergy and Asthma Proceedings can be contacted at: Ocean Side Publications Inc, 95 Pitman St, Providence, RI 02906, USA (see also Biotechnology).

Our news journalists report that additional information may be obtained by contacting L. Bielory, Merck & Co Inc, Global Hlth Outcomes, Whitehouse Stn, NJ, United States. Additional authors for this research include D.P. Skoner, M.S. Blaiss, B. Leatherman, M.S. Dykewicz, N. Smith, G. Ortiz, J.A. Hadley, N. Walstein, T.J. Craig and F. Allen-Ramey.

Keywords for this news article include: Biotechnology, New Jersey, United States, Immunotherapy, Immunomodulation, Whitehouse Station, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Immunotherapy Weekly

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters